Aeglea biotherapeutics, inc. (AGLE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenues:
Grant

-

-

-

-

-

3,888

5,171

6,650

0

-

0

0

-

-

-

-

-

-

-

-

-

Grant

-

-

-

-

-

-

-

-

-

-

-

-

4,751

-

4,966

4,890

6,944

6,085

0

0

0

Operating expenses:
Research and development

64,773

64,600

58,832

49,922

44,238

36,719

30,713

28,023

24,736

22,815

21,765

20,911

19,496

18,143

17,367

15,111

13,427

11,453

0

0

0

General and administrative

16,926

15,734

14,898

13,905

13,015

12,632

11,443

11,149

10,587

10,066

9,796

8,841

8,925

8,391

7,959

7,255

6,930

5,947

0

0

0

Total operating expenses

81,699

80,334

73,730

63,827

57,253

49,351

42,156

39,172

35,323

32,881

31,561

29,752

28,421

26,534

25,326

22,366

20,357

17,400

0

0

0

Loss from operations

-81,699

-80,334

-73,730

-63,827

-54,875

-45,463

-36,785

-32,540

-29,590

-27,676

-26,592

-24,895

-23,670

-21,906

-20,360

-17,476

-13,413

-11,315

0

0

0

Other income (expense):
Interest income

1,936

2,143

2,138

1,892

1,536

1,172

896

693

530

482

403

339

313

244

183

116

47

22

0

0

0

Other expense, net

-52

-63

-65

-66

-57

-57

-44

-43

-48

-42

-47

-44

-41

-36

-25

0

0

-

0

-

-

Total other income

1,884

2,080

2,073

1,826

1,479

1,115

852

650

482

440

356

295

272

208

158

99

39

20

0

0

0

Net loss

-79,815

-78,254

-71,657

-62,001

-53,396

-44,348

-35,933

-31,890

-29,108

-27,236

-26,236

-24,600

-23,398

-21,698

-20,202

-17,377

-13,374

-11,295

0

0

0

Deemed dividend to convertible preferred stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

228

0

0

0

Net loss per share, basic and diluted

-0.57

-0.65

-0.66

-0.55

-0.59

-0.64

-0.54

-0.46

-0.49

-0.38

-0.48

-0.47

-0.47

5.81

-0.47

-0.46

-7.10

-6.49

-5.57

-2.44

-4.71

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,523

0

0

0

Weighted-average common shares outstanding, basic and diluted

33,097

33,052

32,894

32,840

29,011

24,032

21,986

20,598

16,672

16,622

16,409

14,114

13,365

13,424

13,326

11,776

640

627

612

585

573